Resultados de Búsqueda por Autor

1

artículo

SELNET clinical practice guidelines for bone sarcoma

Publicado por
Blay, JY, Palmerini, E, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Chs, CS, Carvajal Montoya, A, Casavilca-Zambrano, S, Castro-Oliden, V, Chacón, M, Clara-Altamirano, MA, Collini, P, Correa Genoroso, R, Costa, FD, Cuellar, M, Dei Tos, AP, Dominguez Malagon, HR, Donati, DM, Dufresne, A, Eriksson, M, Farias-Loza, M, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gerderblom, H, Gouin, F, Gómez-Mateo, MC, Gronchi, A, Haro, J, Hindi, N, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, Lopes, A, Lopes David, BB, Lopez-Pousa, A, Lutter, G, Maki, RG, Martinez-Said, H, Martinez-Tlahuel, JL, Mello, CA, Morales Pérez, JM, Moura, DS, Nakagawa, SA, Nascimento, AG, Ortiz-Cruz, EJ, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Santos, TG, Scotlandi, K, Mlg S, Soulé T, Stacchiotti, S, Valverde, CM, Waisberg, F, Zamora Estrada, E, Martin-Broto, J

Publicado 2022

Enlace

Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consorti...

2

artículo

SELNET clinical practice guidelines for soft tissue sarcoma and GIST

Publicado por
Blay, JY, Hindi, N, Bollard, J, Aguiar, S Jr, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sánchez, CHS, Carvajal, B, Carvajal Montoya, A, Casavilca-Zambrano, S, Castro-Oliden, V, Chacón, M, Clara, M, Collini, P, Correa Genoroso, R, Costa, FD, Cuellar, M, Dei Tos, AP, Dominguez Malagon, HR, Donati, D, Dufresne, A, Eriksson, M, Farias-Loza, M, Fernandez, P, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gelderblom, H, Gouin, F, Gómez-Mateo, MC, Gronchi, A, Haro, J, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, Lopes David, BB, Lopez-Pousa, A, Lutter, G, Martinez-Said, H, Martinez-Tlahuel, J, Mello, CA, Morales Pérez, JM, Moura David, S, Nascimento, AG, Ortiz-Cruz, EJ, Palmerini, E, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Salas, R, Santos, TTG, Scotlandi, K, Soule, T, Stacchiotti, S, Valverde, C, Waisberg, F, Zamora Estrada, E, Martin-Broto, J

Publicado 2022

Enlace

Soft tissue sarcoma (STS) and gastrointestinal tumors (GIST) encompass > 80 different histologic subtypes. Clinical practice guidelines for STS and GIST still lack in Latin-American countries. Tailored clinical guidelines are instrumental to improve outcome in sarcoma patients in LatinAmerican countries. This is the first review establishing STS and GIST guidelines for the purpose of LatinAmerican clinical practices to our knowledge.

3

artículo

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

Publicado por
El Bairi, K, Haynes, HR, Blackley, E, Fineberg, S, Shear, J, Turner, S, de Freitas, JR, Sur, D, Amendola, LC, Gharib, M, Kallala, A, Arun, I, Azmoudeh-Ardalan F, Fujimoto, L, Sua, LF, Liu, SW, Lien, HC, Kirtani, P, Balancin, M, El Attar, H, Guleria, P, Yang WShash, E, Chen, IC, Bautista, V, Do Prado Moura, JF, Rapoport, BL, Castaneda, C, Spengler, E, Acosta-Haab, G, Frahm, I, Sanchez, J, Castillo, M, Bouchmaa, N, Md Zin, RR, Shui, R, Onyuma, T, Yang, W, Husain, Z, Willard-Gallo, K, Coosemans, A, Perez, EA, Provenzano, E, Ericsson, PG, Richardet, E, Mehrotra, R, Sarancone, S, Ehinger, A, Rimm, DL, Bartlett, JMS, Viale, G, Denkert, C, Hida, AI, Sotiriou, C, Loibl, S, Hewitt, SM, Badve, S, Symmans, WF, Kim, RS, Pruneri, G, Goel, S, Francis, PA, Inurrigarro, G, Yamaguchi, R, Garcia-Rivello, H, Horlings, H, Afqir, S, Salgado, R, Adams, S, Kok, M, Dieci, MV, Michiels, S, Demaria S, Loi, S, International Immuno-Oncology Biomarker Working Group

Publicado 2021

Enlace

The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) t...